Jim Jasper

Lupus Research Alliance and Lupus Therapeutics – Leading Voices in Trial Diversity

|

New York, NY, June 25, 2019 — Caroline Donovan, Manager of Patient Engagement at Lupus Research Alliance (LRA) affiliate Lupus Therapeutics (LT) took part in a panel discussion at the DIA 2019 (Drug Information Association) annual meeting, aimed at finding ways to make sure that diverse groups of patients can make informed choices about joining … Lupus Research Alliance and Lupus Therapeutics – Leading Voices in Trial Diversity

VALUE Study Results Reported at EULAR

|

Madrid, Spain, June 13, 2019 — Results of the first clinical trial sponsored by the Lupus Research Alliance and conducted through its Lupus Clinical Investigators Network (LuCIN) were presented today at the European Congress of Rheumatology (EULAR) 2019.  Entitled VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool (VALUE), the study showed that a … VALUE Study Results Reported at EULAR

Taking Scientific Discovery: From Lab Bench to You

|

New York, NY, April 8, 2019 — Making new and efficacious lupus therapies available to patients has long been a major focus of the Lupus Research Alliance, and today we’ve taken an important step toward that aim. Based on a breakthrough discovery made by Betty Diamond, MD of Feinstein Institutes for Medical Research, Meggan Mackay, MD, MS, … Taking Scientific Discovery: From Lab Bench to You

Lupus Therapeutics Partners with Takeda to Test Potential Treatment for Lupus

|

New York, NY, March 1, 2019 — The Lupus Research Alliance and its affiliate, Lupus Therapeutics announced a collaboration with Takeda Pharmaceutical Company Limited, to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916).  The national study will be conducted in 20 research centers throughout the … Lupus Therapeutics Partners with Takeda to Test Potential Treatment for Lupus

Lupus Therapeutics Launches Peer Training Program to Help Patients Benefit from Clinical Trials

|

New York, NY, February 1, 2019 — Today, Lupus Therapeutics, an affiliate of Lupus Research Alliance, is launching our Patient Advocates for Lupus Studies (PALS) program with a pilot study to determine its effectiveness in increasing awareness of and participation in lupus clinical trials, particularly among diverse populations.  The program will pair people with lupus interested … Lupus Therapeutics Launches Peer Training Program to Help Patients Benefit from Clinical Trials

Lupus Research Alliance and Lupus Therapeutics Partner on New Phase 3 Trial Testing Potential Benefit of Ustekinumab (Stelara®) in Lupus

|

New York, NY, February 1, 2019 — The Lupus Research Alliance announced that its affiliate Lupus Therapeutics is working with the pharmaceutical company, Janssen, to help conduct a Phase 3 trial to evaluate whether their drug ustekinumab (Stelara®) may offer benefit to people with lupus.  Called LOTUS, the international study is being conducted in over … Lupus Research Alliance and Lupus Therapeutics Partner on New Phase 3 Trial Testing Potential Benefit of Ustekinumab (Stelara®) in Lupus

Lupus Research Alliance and Lupus Therapeutics collaborate with Bristol-Myers Squibb on a New Lupus Trial

|

New York, NY, April 26, 2018 — Lupus Research Alliance and Lupus Therapeutics collaborate with Bristol-Myers Squibb on a New Lupus Trial The Lupus Research Alliance today announced a collaboration between its newly formed affiliate, Lupus Therapeutics, and the pharmaceutical company, Bristol-Myers Squibb (BMS), to test a novel investigational drug, BMS-986165, as a potential new therapy … Lupus Research Alliance and Lupus Therapeutics collaborate with Bristol-Myers Squibb on a New Lupus Trial

Lupus Research Alliance LuCIN Clinical Trials Network Launches Inaugural Studies

|

New York, NY, October 31, 2017 — The Lupus Research Alliance today announced the first clinical trials to be conducted through its Lupus Clinical Investigators Network (LuCIN) aimed at discovering new treatments for the millions of people around the globe living with lupus. Recognizing the limited treatments for lupus, LuCIN was organized, managed and is … Lupus Research Alliance LuCIN Clinical Trials Network Launches Inaugural Studies

New Smartphone App VALUE May Enable Lupus Patients to Report Symptoms Easily and Accurately

|

New York, NY, May 10, 2017 — App developed by Lupus Research Alliance, Pfizer Inc. and Tata to be tested through non-interventional clinical trial called VALUE The Lupus Research Alliance, the world’s largest private funder of lupus research, and Pfizer Inc., the global biopharmaceutical company, announced the start of a non-interventional clinical study that will test … New Smartphone App VALUE May Enable Lupus Patients to Report Symptoms Easily and Accurately

Lupus Research Alliance Launches Clinical Trial Network

|

New York, NY, October 18, 2016 — The Lupus Research Alliance launched a bold initiative, the Lupus Clinical Investigators Network (LuCIN) to accelerate the identification and development of new therapies to treat lupus. Comprised of leading lupus experts at 58 academic research centers throughout North America, LuCIN provides a coordinated framework to test potential new treatments quickly and cost-effectively while upholding … Lupus Research Alliance Launches Clinical Trial Network